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Although little is known of the causes of acute leukaemia in adults,
generally accepted risk factors include ionizing radiation, benzene
and cytotoxic therapy. Because tobacco smoke contains benzene
and radioactive compounds, as well as nitrosamines and urethanes,
which have been found to be leukaemogenic in animal experi-
ments (Vesselinovitch and Mihailovich, 1966; Shisa et al, 1975),
the hypothesis that tobacco is associated with leukaemia seems
plausible. In their 1986 review, Austin and Cole concluded that the
epidemiological evidence suggested a weak association between
smoking and leukaemia, recommending that future investigations
separate lymphoid and myeloid lineages and collect detailed
smoking histories. The current report presents the findings for
smoking obtained from a large population-based case–control
study of acute myeloid and acute lymphoblastic leukaemia.
MATERIALS AND METHODS
The Leukaemia Research Fund’s (LRF) case–control study of
adult acute leukaemia ran from 1 April 1991 to 31 December 1996
in the English regional health authorities of South West, Wessex
and Yorkshire, and the counties of Lancashire and Cumbria. Cases
were all persons newly diagnosed with acute leukaemia during the
study period, aged between 16 and 69 years old, and normally
resident in the study area. Ascertainment was through weekly or
monthly visits by trained investigators to haematological depart-
ments of all hospitals in, and on the peripheries, of the study area.
Diagnoses were confirmed pathologically. Patients were ineligible
if, prior to their diagnosis of acute leukaemia, a definite diagnosis
of chronic myeloid leukaemia or myelodysplastic syndrome had
been made in the previous 6 months, if they had had any other
malignancy in the previous 2 years, or if they had Fanconi’s
anaemia. Cases were also excluded if they had lived abroad for 
6 months or more in the year prior to diagnosis. Following consent
from the treating consultant, eligible patients were asked to partic-
ipate in the study. Cases were usually contacted within 2 weeks of
diagnosis or during the first remission (between 4 and 6 weeks
after diagnosis). If the patient died before an interview was
arranged, their partner or a closerelative was approached, with the
permission of the case’s treating consultant or general practitioner
(GP), between 3 months and a year after death to act as a surro-
gate. Interviews were not undertaken with any patient who had
insufficient command of English, was unable to communicate, or
had severe mental disturbance where no suitable surrogate was
available.
Two controls per case, individually matched to the case on sex,
year of birth, ethnic origin and residence at diagnosis, were
randomly selected from general practice lists; the majority being
selected from the general practice where the case was registered. If
the GP of the case refused, an adjacent general practice was
approached. In Somerset, ethical committee permission for control
selection from general practice lists was not granted, and controls
were randomly selected by the Family Health Services Authority.
Following consent from their GP, potential controls were sent a
letter asking them to participate. If no reply was received within 2
weeks, an attempt was made to contact them by telephone, and if no
reply was received after a month, another control was approached.
A total of 1066 acute leukaemia patients were identified.
Interviews were obtained for 838 (79%) cases; 731 (87%) being
with the case and 107 (13%) being with a surrogate. Permission to
interview was refused by 40 (4%) consultants, 18 (2%) patients
and 21 (2%) surrogates. A further 149 (14%) cases were not inter-
viewed, either because a suitable surrogate could not be found, the
patient could not be traced, or the subject was interviewed for
another study. For the 838 interviewed cases, 3100 controls were
asked to participate. Of the controls who were contacted success-
fully, 1658 (66%) agreed to participate and 854 (34%) refused. It is
possible that the majority of the 588 potential controls who could
not be contacted would have moved from the address supplied by
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All participating subjects were asked to complete a pre-
interview form, containing details of residential, occupational and
medical history. Subjects were subsequently interviewed face-to-
face by trained personnel using a highly structured questionnaire.
Topics covered included residential history, previous occupations
and their exposures, medical history and familial cancer as well as
smoking history. Exposure to tobacco was defined as the subject
having smoked at least once a day for at least 6 months. Every
change in habit, such as the type of tobacco smoked, and the
number of cigarettes smoked per day, was recorded with the corre-
sponding start and stop dates. A 2-year latent interval prior to diag-
nosis is assumed, based on the minimum induction period between
initial exposure and the onset of leukaemia observed in cohorts
exposed to known leukaemogens (Smith and Doll, 1982; Curtis et
al, 1984; Aksoy, 1985; Rinsky et al, 1987).
A deprivation indicator was created using the address at diag-
nosis. For each address, the postcode was validated against the
Post Office Postcode Address File using QuickAddressTM (v2.0)
and matched to a 1991 census small area, or ‘enumeration district’,
via the PC2ED program available from Manchester Computing
Service (MIDAS). Townsend scores were computed for each
enumeration district in England and Wales using data from the
1991 census (Townsend et al, 1988). Categorization of the
resulting continuous variable provided a coding scheme for the
enumeration districts of the addresses at diagnoses.
Odds ratios (OR) and 95% confidence intervals (CI) for
matched analyses were calculated using conditional logistic
regression (Breslow and Day, 1980). Tests for trend were
conducted using the likelihood-ratio test and the lowest exposure
category was defined as the reference group. All analyses were
performed using STATA (Stata Corporation, 1997).
RESULTS
Among white interviewed cases, 695 (86%) were diagnosed
with acute myeloid leukaemia (AML), 100 (12%) with acute
lymphoblastic leukaemia (ALL) and 12 (1%) had unspecified
acute leukaemia (Table 1). A slightly higher proportion of cases
than controls were single and had left school before the age of 17
years. Although these differences were not statistically significant,
interviewed cases were more likely to live in deprived areas than
their corresponding controls (c2 = 13.67, P = 0.03). Consequently,
deprivation was adjusted for in the subsequent analyses.
Table 2 shows the number of cases and controls by reported
smoking status 2 years before diagnosis. For all acute leukaemia
combined, 505 (63%) cases and 943 (59%) controls reported that
they had regularly smoked tobacco (OR = 1.2, 95% CI 1.0–1.4).
Compared with non-smokers, the effect was stronger in current
smokers (OR = 1.4, 95% CI 1.1–1.7) than in ex-smokers (OR =
1.0, 95% CI 0.8–1.2). No increased risk was evident among those
who smoked for fewer than 10 years (OR = 0.9, 95% CI 0.7–1.2).
The odds ratio for those who had smoked for 10–19 years was 1.3
(95% CI 1.0–1.8), with similar risks among those who smoked for
20–29 years, 30–39 years, or 40 or more years, and so no signifi-
cant linear dose–response relationship was evident.
Although the risk reduced rapidly as the number of years
stopped smoking increased, there was no significant linear trend
(c2 = 0.54, P = 0.76). Further, among smokers, there was no
evidence of a dose–response relationship with the number of ciga-
rettes smoked per day at 2 years prior to diagnosis: compared with
those who smoked fewer than 15 cigarettes a day, the odds ratios
for those smoking 15–24, and 25 or more cigarettes were 1.3 (95%
CI 0.7–2.5) and 1.0 (95% CI 0.5–2.1) respectively. The numbers of
subjects smoking other types of tobacco were small, but as far as
we could tell, the risks were no different to that for cigarette
smokers (data not shown).
The majority of cases were diagnosed with AML and the odds
ratios for this cell type are generally equivalent to those for all
acute leukaemia combined. Although none of the odds ratios for
ALL were significantly raised, the point estimates are similar to
those for AML.
DISCUSSION
The main finding is an association between tobacco use and acute
leukaemia, which appears to be present for both AML and ALL.
The data suggest that the risk is greatest amongst subjects who
have smoked for at least 10 years. Further, the risk is elevated
among current smokers, and declines to the risk of a non-smoker
soon after cessation of smoking. However, no significant
dose–response trends were observed, either with number of years
smoked or with number of cigarettes smoked per day.
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Table 1 Distribution of white interviewed cases and controls by lineage,
marital status, age left school, and deprivation
Variable Cases Controls
n (%) n (%)
Total 807 (100) 1593 (100)
Diagnosisa
AML 695 (86) –
ALL 100 (12) –
Other 12 (1) –
Marital status
Single 138 (17) 220 (14)
Married 549 (68) 1154 (72)
Divorced/separated 64 (8) 116 (7)
Widowed 32 (4) 66 (4)
Other 24 (3) 37 (2)
Age left school
≤16 673 (83) 1277 (80)
>16 126 (16) 301 (19)
Still at school 7 (1) 15 (1)
Not known 1 (0) 0 (0)
Deprivationb
1 (least deprived) 135 (17) 331 (21)
2 141 (17) 290 (18)
3 137 (17) 282 (18)
4 114 (14) 224 (14)
5 111 (14) 197 (12)
6 90 (11) 162 (10)
7 (most deprived) 76 (9) 99 (6)
Not known 3 (0) 8 (1)
aALL = acute lymphoblastic leukaemia; AML = acute myeloid leukaemia.
Other acute leukaemias includes five cases of acute biphenotypic leukaemia
and seven cases of unspecified acute leukaemia. bDeprivation coded using
categories of the Townsend scores for England and Wales; cases are more
likely to live in deprived areas than their matched controls (Pearson’s c2 =
13.67, P = 0.03).While published evidence for leukaemia and self-reported
tobacco use is inconclusive (Kinlen and Rogot, 1988; Brownson,
1989; McLaughlin, 1989; Garfinkel and Boffetta, 1990; Mills et
al, 1990; Spitz et al, 1990; Brownson et al, 1991; Linet et al, 1991;
Brown et al, 1992a; Sandler et al, 1993; McLaughlin et al, 1995;
Engeland et al, 1996; Adami et al, 1998), studies tend to suggest a
weak association for AML (Severson, 1987; Brownson, 1989;
Severson et al, 1990; Brownson et al, 1991; Brown et al, 1992a;
Friedman, 1993; Sandler et al, 1993; Mele et al, 1994; Pasqualetti
et al, 1997), with only a few studies not reporting an increased risk
(Cartwright et al, 1988; Kabat et al, 1988; Spitz et al, 1990; Crane
et al, 1992). Indeed, pooling the odds ratios from all case–control
studies published to date suggests that smoking could increase the
risk of AML by about 20% (Table 3). This increase is similar to
those reported in previous meta-analyses (Brownson et al, 1993;
Siegel, 1993). However, these estimates should be treated
cautiously since there is strong evidence of heterogeneity between
studies, possibly arising from heterogeneous populations and/
or different study designs (Hardy and Thompson, 1998).
Interestingly, the pooled risk estimate changes little when only
population-based case–control studies (Severson, 1987; Severson
et al, 1990; Brown et al, 1992a; Sandler et al, 1993; and the
present study) are considered, despite there being less evidence of
heterogeneity (c2 = 4.99, P = 0.29).
Published evidence does not favour an association between ALL
and smoking (Kabat et al, 1988; Brown et al, 1992a; Sandler et al,
1993; Mele et al, 1994; Pasqualetti et al, 1997), possibly as many
studies lack power to detect a significant risk due to small numbers
of cases. Indeed, only one case–control study of comparable size to
the present has been published, with a risk estimate and 95% confi-
dence interval (OR = 1.3, 95% CI 0.8–2.0) similar to the result
reported here (Sandler et al, 1993). This suggests that the increased
risk from smoking for ALL may be similar to that for AML.
Dose–response relationships for AML and ALL have previ-
ously been evaluated using the number of cigarettes consumed per
day (Kabat et al, 1988; Brownson, 1989; Severson et al, 1990;
Brownson et al, 1991; Brown et al, 1992a; Crane et al, 1992;
Friedman, 1993), the number of years smoked (Severson, 1987;
Severson et al, 1990; Brown et al, 1992a; Friedman, 1993), or
pack-years (Severson et al, 1990; Crane et al, 1992; Sandler et al,
1993; Mele et al, 1994). While the majority of studies found no
evidence of a trend in risk with number of cigarettes smoked per
day (Kabat et al, 1988; Brownson, 1989; Brownson et al, 1991;
Brown et al, 1992a; Crane et al, 1992), significant increasing
trends with increasing number of years smoked were found in two
studies (Severson, 1987; Severson et al, 1990). More consistent
with this study were the relatively constant odds ratios for AML
with years smoked observed in another study (Brown et al,
1992a). Although significant increasing trends of pack-years were
reported in previous studies (Severson et al, 1990; Sandler et al,
1993; Mele et al, 1994), it was felt that for the current analysis
pack-years were inappropriate as not only does this variable not
account for time with respect to diagnosis, it also accrues errors
resulting from recall bias. Moreover, the presented results suggest
that those who stopped smoking over 20 years before diagnosis
were not at risk and so an analysis of lifetime exposure expressed
in pack-years is probably unsuitable.
Evidence that current smokers have increased risk of acute
leukaemia has been found in three other case–control studies
(Severson et al, 1990; Brown et al, 1992a; Mele et al, 1994).
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Table 2 Number of cases and controls, adjusted odds ratiosa, and 95% confidence intervals by lineage for smoking status, number of years smoked, and
number of years since stopped smoking up to 2 years prior to diagnosis using never smoked as reference
Variable Acute leukaemia AMLb ALLb
Case Control ORa 95% CI Case Control ORa 95% CI Case Control ORa 95% CI
(n = 807) (n = 1593) (n = 695) (n = 1374) (n = 100) (n = 196)
Smoking status
Never 295 647 1.0 – 251 549 1.0 – 38 88 1.0 –
Ever 505 943 1.2 (1.0–1.4) 438 822 1.2 (1.0–1.4) 61 108 1.3 (0.8–2.2)
Not known 7 3 6 6 1 0
Current 295 461 1.4 (1.1–1.7) 257 389 1.4 (1.1–1.8) 37 64 1.3 (0.7–2.3)
Past 207 472 1.0 (0.8–1.2) 178 424 0.9 (0.7–1.2) 24 43 1.3 (0.7–2.5)
Not Known 3 10 3 9 0 1
Years smokedc
<10 95 219 0.9 (0.7–1.2) 78 179 0.9 (0.7–1.3) 16 37 1.0 (0.5–2.0)
10–19 120 202 1.3 (1.0–1.8) 95 170 1.2 (0.9–1.7) 23 30 2.1 (0.9–4.7)
20–29 103 186 1.2 (0.9–1.7) 94 165 1.3 (0.9–1.7) 8 19 1.0 (0.4–2.6)
30–39 96 177 1.2 (0.9–1.7) 87 156 1.3 (0.9–1.8) 7 16 1.0 (0.4–2.8)
40+ 82 144 1.4 (1.0–2.0) 75 139 1.3 (0.9–1.9) 7 4 10.6 (1.2–90.5)
Not known 9 15 9 13 0 2
Years stoppedd
21+ 54 151 0.8 (0.5–1.1) 47 140 0.7 (0.5–1.0) 4 9 1.0 (0.3–4.0)
11–20 61 133 1.0 (0.7–1.4) 56 120 1.0 (0.7–1.5) 4 10 0.9 (0.2–3.4)
1–10 92 188 1.1 (0.8–1.4) 75 164 1.0 (0.7–1.4) 16 24 1.5 (0.7–3.1)
Current 295 461 1.4 (1.1–1.7) 257 389 1.4 (1.1–1.8) 37 64 1.3 (0.7–2.3)
Not known 3 10 3 9 0 1
aOdds ratio adjusted for deprivation, estimated using conditional logistic regression. bALL = acute lymphoblastic leukaemia; AML = acute myeloid leukaemia.
cTests for trend in number of years smoked uses <10 years as baseline; c2 = 0.81 (P = 0.85) for acute leukaemia, c2 = 0.18 (P = 0.98) for AML, and c2 = 11.54
(P < 0.01) for ALL. dTests for trend in number of years since stopped uses 21+ years as baseline; c2 = 0.54 (P = 0.76) for acute leukaemia, c2 = 1.64 (P = 0.44)
for AML, and c2 = 0.79 (P = 0.68) for ALL.Unlike our report, however, these studies also found associations
for ex-smokers. This difference probably reflects the fact that, like
others (Smith and Doll, 1982; Curtis et al, 1984; Aksoy, 1985;
Rinsky et al, 1987), we lagged the exposure data 2 years before
diagnosis, partly to account for latency and partly because of
concerns about changing habits as the illness onsets. Hence, indi-
viduals who gave up smoking within the 2 years leading up to
diagnosis would have been classified as a current smoker in our
study and as an ex-smoker (even if given up in the week before
diagnosis) in other studies (Severson et al, 1990; Brown et al,
1992a; Mele et al, 1994). One of these studies also suggested
decreasing risks with increasing number of years since quit
smoking, but this result was based on small numbers (Severson et
al, 1990).
The level of completeness of cases in this study is known to be
high as all cases are registered on the Leukaemia Research Fund’s
Data Collection Study (Cartwright et al, 1997), which is estimated
to be 98.5% complete for AML and ALL (McNally et al, 1997). Of
more concern is the high number of non-participating subjects.
Cases and controls who refused to participate tended to live in
more deprived areas than interviewed subjects, and so were more
likely to smoke (Hay and Foster, 1984; Bennett et al, 1996). As the
refusal rate for controls is considerably higher than for cases, the
resulting risk estimates may be overestimated. However, adjust-
ment for deprivation did not alter the association of tobacco expo-
sure and acute leukaemia (unadjusted OR = 1.2, 95% CI 1.0–1.4).
A major problem with case–control studies of the type reported
here is the retrospective collection of self-reported exposure infor-
mation. As smoking is not a widely accepted cause of leukaemia,
exaggeration of exposure by cases seems improbable. While
under-reporting by controls cannot be ruled out, the smoking
habits reported appear consistent with a sample of the general
population (Bennett et al, 1996). For diseases with poor prognosis,
a further problem surrounds the issue of surrogate interviews. If
they are not attempted, then the completeness of the study is
compromised. On the other hand, surrogate information about
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Table 3 Odds ratios for ever smoked cigarettes up to interview with 95% confidence intervals for acute myeloid leukaemia from case–control studies published
after Austin and Cole’s 1986 review
Reference Period Cases Controls n OR 95% CI
Country Age
Kane et al 1999c 1991–1996 807 acute leukaemias 1593 695 1.2a,b (1.0–1.4)
England 16–69
Pasqualletti et al 1997 1972–1997 1216 haematological 1216 73 2.3a (1.1–4.8)
Italy 16–91 malignancies
Mele et al 1994 1986–1990 277 leukaemias or refractory 467 118 1.4 (1.0–1.9)
Italy ³30 anaemia with excess blasts
Sandler et al 1993c 1986–1989 610 acute leukaemias 618 423 1.2b (0.9–1.5)
USA 18–79
Brown et al 1992ac 1981–1984 578 leukaemias 1245 114 1.4a (0.9–2.2)
USA ³30
Crane et al 1992 1982–1983 60 AML 60 60 0.6 (0.3–1.4)
USA ³18
Brownson et al 1991 1984–1990 1648 leukaemias 5138 189 1.5 (1.1–2.1)
USA ³20
Severson et al 1990 1981–1984 106 AML 128 93 2.1 (1.2–3.9)
USA 20–79
Spitz et al 1990 1985–1988 241 leukaemias 240 34 0.8 (0.4–1.5)
USA
Brownson 1989 1984–1987 725 leukaemias 2922 238 1.4a (1.0–1.9)
USA ³20
Cartwright et al 1988 1979–1986 161 AML 310 161 0.6 (0.4–1.0)
England ³15
Kabat et al 1988 1969–1985 562 leukaemias 9342 156 0.8a (0.6–1.1)
USA 20–80
Severson 1987c 1981–1984 114 AML 133 98 1.8 (1.0–3.2)
USA 20–79
Combinedd – all studies 1.2 (1.0–1.4)
Combinedd – excluding Kane et al 1.2 (1.0–1.5)
Combinedd – population-based studies 1.3 (1.1–1.4)
aOdds ratios for ever smoked any tobacco. bSmoking status lagged by 2 years (Kane et al, 1999) and by 1 year (Sandler et al, 1993) prior to diagnosis.
cPopulation-based studies. dTest for heterogeneity gives c2 = 32.61 (P < 0.01) for all studies combined, c2 = 32.61 (P < 0.01) for all studies except Kane et al
1999, and c2 = 4.99 (P = 0.29) for population-based studies.factors such as smoking may be poor. Fortunately, the quick
referral of cases into our study ensured that only a small propor-
tion of interviews (13%) were with surrogates. Removing the few
proxy interviews made little difference to the risk estimate for ever
compared with never smoked (OR = 1.2, 95% CI 1.0–1.5 based on
702 cases and 1385 controls), and the odds ratios for the number of
years smoked and the number of years since quit were similarly
unaffected (data not shown).
As the effect of smoking on the risk of acute leukaemia appears
to be comparatively small, confounding by other factors may be
important. Evidence for other risk factors that could be related to
smoking is, however, sparse and contradictory. Nonetheless, it is
unfortunate that information on habits such as alcohol consump-
tion (Williams and Horm, 1977; Jensen, 1979; Blackwelder et al,
1980; Hinds et al, 1980; Schmidt and Popham, 1981; Carstensen et
al, 1990; Brown et al, 1992b) and variations in diet (Hursting et al,
1990; Kwiatkowski, 1993) were not collected in this study.
While our increased risk could be confounded by other risk
factors, a causal relationship between tobacco smoke and acute
leukaemia seems plausible. Known or suspected leukaemogens,
for example benzene, radioactive lead and polonium, nitrosamines
and urethanes, are present in tobacco smoke. The levels of such
chemicals in one packet of 20 cigarettes are considerably less than
in some work environments, so it seems unlikely that any one
chemical constituent of tobacco smoke could solely cause the
increased risk of acute leukaemia. Although the biological mecha-
nisms are unknown, tobacco smoke has been associated with
chromosomal defects in the peripheral blood (Perera et al, 1987),
immunological changes such as increases in the leucocyte count
(Petitti and Kipp, 1986) and decreases in natural killer cell activity
(Hersey et al, 1983); all factors that are linked to leukaemia
(Heath, 1982). In addition, long-term use exacerbates such
changes (Ghosh and Ghosh, 1987; Petitti and Kipp, 1986) while
quitting results in a subsequent decline in the leucocyte count
(Petitti and Kipp, 1986), an increase in natural killer cell activity
(Hersey et al, 1983) and a decrease in DNA damage (Frenzilli et
al, 1997). Hence, our observed increased risk of acute leukaemia
with 10 or more years of tobacco use and a decline in the odds
ratios with increasing number of years since stopping seems
reasonable.
In conclusion, AML was found to be associated with smoking,
and the risk was greatest for those who smoked for 10 or more
years and who were still smoking at 2 years before diagnosis. It
appears that the risk of ALL from tobacco was no different to the
risk of AML, but small numbers have hampered our investigation.
Although no trend was observed for number of years smoked or
number of cigarettes per day, there was evidence that the risk of
acute leukaemia decreases on cessation of smoking.
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